Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Article Type
Date
Availability
1-13 of 13
Keywords: metformin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2024) 138 (2): 87–102.
Published: 12 January 2024
... to influence paracellular junctional composition and permeability. WJ-MSCs were isolated from human umbilical cords from normal pregnancies (nWJ-MSCs, n =13) and those complicated by GDM (gWJ-MSCs), either diet-controlled (d-GDM, n =13) or metformin-treated (m-GDM, n =9). We recorded that 4-fold more WJ-MSCs...
Articles
Shuya Gao, Qingchen Yang, Zekun Liu, Weixian Kong, Jiawen Chen, Xie Li, Yue Peng, Mengmeng Bao, Xiaohong Bian, Yuexin Zhang, Qizhou Jiang, Zhe Li, Yubin Zhang, Fangrong Yan, Junmei Ye
Journal:
Clinical Science
Clin Sci (Lond) (2022) 136 (22): 1711–1730.
Published: 30 November 2022
...Shuya Gao; Qingchen Yang; Zekun Liu; Weixian Kong; Jiawen Chen; Xie Li; Yue Peng; Mengmeng Bao; Xiaohong Bian; Yuexin Zhang; Qizhou Jiang; Zhe Li; Yubin Zhang; Fangrong Yan; Junmei Ye Metformin is accepted as a first-line drug for the therapy of Type 2 diabetes (T2D), while its mechanism is still...
Includes: Supplementary data
Articles
Surya Ramachandran, Vinitha Anandan, V. R. Kutty, Ajit Mullasari, M. Radhakrishna Pillai, Cheranellore Chandrasekharan Kartha
Journal:
Clinical Science
Clin Sci (Lond) (2018) 132 (6): 719–738.
Published: 30 March 2018
... effects, during hyperglycemic conditions, increases lipid uptake in macrophages by increasing scavenger receptors on the cell’s surface. It also promotes macrophage migration across endothelial cells and conversion of macrophages into foam cells. Given the known effects of metformin in reducing vascular...
Includes: Supplementary data
Articles
François Cauchy, Mouniya Mebarki, Benjamin Leporq, Samira Laouirem, Miguel Albuquerque, Simon Lambert, Pierre Bourgoin, Olivier Soubrane, Bernard E. Van Beers, Sandrine Faivre, Pierre Bedossa, Valérie Paradis
Journal:
Clinical Science
Clin Sci (Lond) (2017) 131 (1): 27–36.
Published: 09 December 2016
...François Cauchy; Mouniya Mebarki; Benjamin Leporq; Samira Laouirem; Miguel Albuquerque; Simon Lambert; Pierre Bourgoin; Olivier Soubrane; Bernard E. Van Beers; Sandrine Faivre; Pierre Bedossa; Valérie Paradis Studies suggest that metformin, widely used for treating Type 2 diabetes, possesses innate...
Includes: Supplementary data
Articles
Phablo Wendell C. Oliveira, Glauciene J. de Sousa, Izabela F. Caliman, Aline Z. Lamas, Ana Raquel Santos de Medeiros, Tadeu U. de Andrade, Glaucia R. de Abreu, Suely G. de Figueiredo, Nazaré S. Bissoli
Journal:
Clinical Science
Clin Sci (Lond) (2014) 127 (4): 265–275.
Published: 29 April 2014
...Phablo Wendell C. Oliveira; Glauciene J. de Sousa; Izabela F. Caliman; Aline Z. Lamas; Ana Raquel Santos de Medeiros; Tadeu U. de Andrade; Glaucia R. de Abreu; Suely G. de Figueiredo; Nazaré S. Bissoli Metformin is an antihyperglycaemic drug with pleiotropic effects that result in cardiovascular...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2012) 122 (12): 555–573.
Published: 05 March 2012
... pathways that can activate AMPK using isogenic cell lines stably expressing either wild-type AMPK complexes or AMP-insensitive (R531G) γ2 mutants. AMP-activated protein kinase (AMPK) autophagy cardiovascular disease energy sensor metformin stress All living organisms face the challenge...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2012) 122 (6): 253–270.
Published: 11 November 2011
...Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first...
Articles
Jan Benes, Ludmila Kazdova, Zdenek Drahota, Josef Houstek, Dasa Medrikova, Jan Kopecky, Nikola Kovarova, Marek Vrbacky, David Sedmera, Hynek Strnad, Michal Kolar, Jiri Petrak, Oldrich Benada, Petra Skaroupkova, Ludek Cervenka, Vojtech Melenovsky
Journal:
Clinical Science
Clin Sci (Lond) (2011) 121 (1): 29–41.
Published: 18 March 2011
... with altered substrate metabolism. Whether modification of substrate use improves the course of HF remains unknown. The antihyperglycaemic drug MET (metformin) affects substrate metabolism, and its use might be associated with improved outcome in diabetic HF. The aim of the present study was to examine whether...
Includes: Supplementary data
Articles
Thomas Forst, Matthias M. Weber, Mirjam Löbig, Ute Lehmann, Jürgen Müller, Cloth Hohberg, Christiane Friedrich, Winfried Fuchs, Andreas Pfützner
Journal:
Clinical Science
Clin Sci (Lond) (2010) 119 (8): 345–351.
Published: 06 July 2010
... mellitus). The study covered 23 metformin-treated T2DM patients with an HbA 1c (glycated haemoglobin) >6.5%. Patients were randomized to receive either PIO (15 mg, twice a day) or GLIM (1 mg, twice a day) in combination with metformin (850 mg, twice a day) for 6 months. Blood samples were taken...
Articles
Vanessa Souza-Mello, Bianca M. Gregório, Fernando S. Cardoso-de-Lemos, Laís de Carvalho, Márcia B. Aguila, Carlos A. Mandarim-de-Lacerda
Journal:
Clinical Science
Clin Sci (Lond) (2010) 119 (6): 239–250.
Published: 08 June 2010
... weight·day −1 ), HF-S (HF diet treated with sitagliptin; 1.08 g·kg −1 of body weight·day −1 ), HF-M (HF diet treated with metformin; 310.0 mg·kg −1 of body weight·day −1 ), HF-TM (HF diet treated with telmisartan+metformin), HF-TS (HF diet treated with telmisartan+sitagliptin) and HF-SM (HF diet treated...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2009) 116 (8): 607–620.
Published: 16 March 2009
...; consequently, they have been implicated in cardiac ischaemia, arrhythmias and hypertrophy. Recent mechanistic studies have shown that AMPK has an important role in the mechanism of action of MF (metformin), TDZs (thiazolinediones) and statins. Increased understanding of the beneficial effects of AMPK...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2008) 114 (3): 251–256.
Published: 08 January 2008
... the aim of the present study was to compare the antioxidant capacities and structural changes in albumin in patients with T2DM (Type 2 diabetes mellitus) treated with MET (metformin) or SU (sulfonylureas) and in healthy control subjects. Structural changes in albumin were studied by fluorescence quenching...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1987) 73 (1): 41–45.
Published: 01 July 1987
...P. Leslie; R. T. Jung; T. E. Isles; J. Baty 1. In the management of the non-insulin dependent diabetic patient, metformin often facilitates weight loss whereas sulphonylurea may predispose to weight gain. To investigate whether this is due to alterations in energy expenditure we have studied energy...